RecruitingNCT06603597

HER2-positive Breast Cancer Registry

Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)

Sponsor

Priyanka Sharma

Enrollment

1,000 participants

Start Date

Sep 27, 2024

Study Type

OBSERVATIONAL

Conditions

HER2 + Breast Cancer

Summary

The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Stage I-IV HER2-positive breast cancer

Exclusion Criteria1

None

Locations(6)

KUCC - Indian Creek

Overland Park, Kansas, United States

KUCC - Overland Park

Overland Park, Kansas, United States

KUCC - Briarcliff

Westwood, Kansas, United States

KUCC - Olathe

Westwood, Kansas, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

KUCC - Lee's Summit

Lee's Summit, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06603597

Related Trials

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT0721117812 locations

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

NCT073934251 location

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT0625387145 locations

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

NCT070815553 locations

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

NCT070654351 location